Article
|
Open Access
Featured
-
-
Article
| Open Access
Immune checkpoint inhibitors for metastatic uveal melanoma: a meta-analysis
- Kayoko Yamada
- , Masaki Takeuchi
- & Nobuyuki Horita
-
Article
| Open Access
Intravenous administration of IL-12 encoding self-replicating RNA-lipid nanoparticle complex leads to safe and effective antitumor responses
- Zihao Wang
- , Yanni Chen
- & Yuanqing Liu
-
Article
| Open Access
Nivolumab plus ipilimumab versus the EXTREME regimen in recurrent/metastatic squamous cell carcinoma of the head and neck: a cost-effectiveness analysis
- Dongmei Ye
- , Xueyan Liang
- & Yan Li
-
Article
| Open Access
Multi-scale geometric network analysis identifies melanoma immunotherapy response gene modules
- Kevin A. Murgas
- , Rena Elkin
- & Allen R. Tannenbaum
-
Article
| Open Access
A novel T cell-redirecting anti-GPRC5D × CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models
- Urara Tomita
- , Yoko Ishimoto
- & Toshinori Agatsuma
-
Article
| Open Access
Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD-1 and IL-10 blockade
- S. K. Daniel
- , K. M. Sullivan
- & V. G. Pillarisetty
-
Article
| Open Access
Risk-adapted locoregional radiotherapy strategies based on a prognostic nomogram for de novo metastatic nasopharyngeal carcinoma patients treated with chemoimmunotherapy
- Yuebing Chen
- , Chuying Chen
- & Cheng Lin
-
Editorial
| Open AccessAdvancing cancer immunotherapy: from innovative preclinical models to clinical insights
The rapid expansion of cancer immunology and immunotherapy builds upon the success of early immune checkpoint inhibitors (ICI) and chimeric antigen receptor T cells for some cancer types. Many gaps still exist, however, in the scientific knowledge of immune dysfunction in the tumour microenvironment and predicting clinical immunotherapy response to allow more cancer patients to benefit from immunotherapy. The Cancer Immunotherapy Collection within Scientific Reports describes pioneering preclinical and clinical studies addressing these concepts, representing significant insights and breakthroughs in the field.
- Andrew W. Craig
- , Hermann B. Frieboes
- & Paula A. Videira
-
Article
| Open Access
FGL2 promotes tumour growth and attenuates infiltration of activated immune cells in melanoma and ovarian cancer models
- Kristianne J. C. Galpin
- , Galaxia M. Rodriguez
- & Barbara C. Vanderhyden
-
Article
| Open Access
Structural basis for the activity and specificity of the immune checkpoint inhibitor lirilumab
- Nicholas Lorig-Roach
- , Nina M. Harpell
- & Rebecca M. DuBois
-
Article
| Open Access
Class II HLA-DRB4 is a predictive biomarker for survival following immunotherapy in metastatic non-small cell lung cancer
- Cindy Y. Jiang
- , Lili Zhao
- & Nithya Ramnath
-
Article
| Open Access
Sinonasal mucosal melanoma treatment response assessment to immune checkpoint inhibitors using hybrid positron emission tomography imaging
- Alexander Maurer
- , Nathalie A. Gstrein
- & Christian M. Meerwein
-
Article
| Open Access
An in vitro model of the macrophage-endothelial interface to characterize CAR T-cell induced cytokine storm
- Robert S. Rosen
- , Jason H. Yang
- & Martin L. Yarmush
-
Article
| Open Access
A novel tumor immunotherapy-related signature for risk stratification, prognosis prediction, and immune status in hepatocellular carcinoma
- Jianping Sun
- , Lefeng Xi
- & Guangying Yang
-
Article
| Open Access
Prognostic value of controlling nutritional status on clinical and survival outcomes in cancer patients treated with immunotherapy
- Jiacheng Zhang
- , Man Li
- & Weixing Wang
-
Article
| Open Access
Overcoming immune checkpoint blockade resistance in solid tumors with intermittent ITK inhibition
- Manzhi Zhao
- , Ling Li
- & Peter D. Katsikis
-
Article
| Open Access
The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer
- Lilian Marie Boll
- , Júlia Perera-Bel
- & Joaquim Bellmunt
-
Article
| Open Access
Risk analysis of fluctuating hypercalcemia after leukapheresis in cellular therapy
- Tomoyasu Jo
- , Yasuyuki Arai
- & Akifumi Takaori-Kondo
-
Article
| Open Access
HLA-DRB1*04:05 is involved in the development of Vogt–Koyanagi–Harada disease-like immune-related adverse events in patients receiving immune checkpoint inhibitors
- Masaki Takeuchi
- , Akira Meguro
- & Nobuhisa Mizuki
-
Article
| Open Access
The effect of blocking immune checkpoints LAG-3 and PD-1 on human invariant Natural Killer T cell function
- Allison L. Balasko
- , Monika M. Kowatsch
- & Keith R. Fowke
-
Article
| Open Access
Fc-competent multispecific PDL-1/TIGIT/LAG-3 antibodies potentiate superior anti-tumor T cell response
- Riyao Yang
- , Su Huang
- & Yue Liu
-
Article
| Open Access
Intact mass analysis reveals the novel O-linked glycosylation on the stalk region of PD-1 protein
- Phanthakarn Tit-oon
- , Arisa Wonglangka
- & Amnart Khongmanee
-
Article
| Open Access
Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy
- Toshihiro Shibutani
- , Risa Goto
- & Shuichi Ohkubo
-
Article
| Open Access
Structural insights into the bi-specific cross-over dual variable antibody architecture by cryo-EM
- David Fernandez-Martinez
- , Mark D. Tully
- & Eaazhisai Kandiah
-
Article
| Open Access
Scalable continuous-flow electroporation platform enabling T cell transfection for cellular therapy manufacturing
- Jacob A. VanderBurgh
- , Thomas N. Corso
- & Harold G. Craighead
-
Article
| Open Access
Development of anti-feline PD-1 antibody and its functional analysis
- Shoma Nishibori
- , Mika K. Kaneko
- & Takuya Mizuno
-
Article
| Open Access
Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment
- Reza Mehdizadeh
- , Seyed Peyman Shariatpanahi
- & Curzio Rüegg
-
Article
| Open Access
Targeting the tumor microenvironment by liposomal Epacadostat in combination with liposomal gp100 vaccine
- Sahar Tahaghoghi-Hajghorbani
- , Mona Yazdani
- & Alireza Rafiei
-
Article
| Open Access
Safety and efficacy of autologous cell vaccines in solid tumors: a systematic review and meta-analysis of randomized control trials
- Donald J. Bastin
- , Joshua Montroy
- & Rebecca C. Auer
-
Article
| Open Access
IL-6/ERK signaling pathway participates in type I IFN-programmed, unconventional M2-like macrophage polarization
- Limin Yang
- , Panpan Guo
- & Jianghuai Liu
-
Article
| Open Access
Vasoactive intestinal peptide blockade suppresses tumor growth by regulating macrophage polarization and function in CT26 tumor-bearing mice
- Wararat Kittikulsuth
- , Daisuke Nakano
- & Akira Nishiyama
-
Article
| Open Access
Activated T cell therapy targeting glioblastoma cancer stem cells
- Ken Miyaguchi
- , Hongqiang Wang
- & John S. Yu
-
Article
| Open Access
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model
- Mohamed Abdelmoneim
- , Ibrahim Ragab Eissa
- & Hideki Kasuya
-
Article
| Open Access
SSTR2 as an anatomical imaging marker and a safety switch to monitor and manage CAR T cell toxicity
- Yago Alcaina
- , Yanping Yang
- & Moonsoo M. Jin
-
Article
| Open Access
A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours
- Yoon-Jung Kang
- , Sophie O’Haire
- & Julia Steinberg
-
Article
| Open Access
Dual-targeted near-infrared photoimmunotherapy for esophageal cancer and cancer-associated fibroblasts in the tumor microenvironment
- Hiroaki Sato
- , Kazuhiro Noma
- & Toshiyoshi Fujiwara
-
Article
| Open Access
Cutaneous adverse events in patients treated with PD-1/PD-L1 checkpoint inhibitors and their association with survival: a systematic review and meta-analysis
- Fangmin Zhao
- , Junjing Zhu
- & Qijin Shu
-
Article
| Open Access
EEG-based grading of immune effector cell-associated neurotoxicity syndrome
- Daniel K. Jones
- , Christine A. Eckhardt
- & M. Brandon Westover
-
Article
| Open Access
Antibody-dependent cellular cytotoxicity-null effector developed using mammalian and plant GlycoDelete platform
- Cho Eun Kang
- , Seungeun Lee
- & Woo Taek Kim
-
Article
| Open Access
A digital platform for the design of patient-centric supply chains
- Niki Triantafyllou
- , Andrea Bernardi
- & Maria M. Papathanasiou
-
Article
| Open Access
Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial
- Tito R. Mendoza
- , David S. Hong
- & Aung Naing
-
Article
| Open Access
Potentiation of combined p19Arf and interferon-beta cancer gene therapy through its association with doxorubicin chemotherapy
- Ruan F. V. Medrano
- , Thiago A. Salles
- & Bryan E. Strauss
-
Article
| Open Access
A novel lipidic peptide with potential to promote balanced effector-regulatory T cell responses
- Michael Agrez
- , Justyna Rzepecka
- & Laura Gallagher
-
Article
| Open Access
Cancer immunohistogram representing cancer-immunity cycle by immunohistochemistry predicts the efficacy of immune checkpoint inhibitors in urological cancer patients
- Toshiki Kijima
- , Terufumi Kubo
- & Takao Kamai
-
Article
| Open Access
Anti-HER2 scFv-CCL19-IL7 recombinant protein inhibited gastric tumor growth in vivo
- Haiqiang Zhang
- , Xueshuai Ye
- & Jianhui Cai
-
Article
| Open Access
Exploration of serum biomarkers in dogs with malignant melanoma receiving anti-PD-L1 therapy and potential of COX-2 inhibition for combination therapy
- Naoya Maekawa
- , Satoru Konnai
- & Kazuhiko Ohashi
-
Article
| Open Access
Next generation automated traceless cell chromatography platform for GMP-compliant cell isolation and activation
- Sabine Radisch
- , Mateusz P. Poltorak
- & Lothar Germeroth
-
Article
| Open Access
The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapy
- Po-Lan Su
- , Jung-Yueh Chen
- & Wu-Chou Su
-
Article
| Open Access
PD-1 blockade enhances chemotherapy toxicity in oesophageal adenocarcinoma
- Maria Davern
- , Rebecca M. O’ Brien
- & Joanne Lysaght
An AI-based approach for modeling the synergy between radiotherapy and immunotherapy